RT Journal
A1 Zhang W, Yang D, Sood AK
T1 BRca1 and brca2 mutations in ovarian cancer—reply
JF JAMA
JO JAMA
YR 2012
FD January 25
VO 307
IS 4
SP 359
OP 361
DO 10.1001/jama.2012.10
UL http://dx.doi.org/10.1001/jama.2012.10
AB 
In Reply:  Drs Buerkle and Tempfer asked whether differences in progression-free survival and primary chemotherapy response between BRCA1 - and BRCA2 -mutated cases could be the result of unbalanced distribution of disease stages and extent of cytoreduction. The distribution of cytoreduction outcomes between BRCA1 - and BRCA2 -mutated cases was similar (P = .94; Table 1 in the article). Although there was an apparent difference in the proportion of stage IV cases between BRCA1- and BRCA2- mutated cases, it was not significant (P = .28).